Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

ESMO Guidelines Committee

doi:10.1016/j.annonc.2020.08.2099

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up^†

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

239 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	1476-1490
Nombre de pages	15
journal	Annals of Oncology
Volume	31
Numéro de publication	11
Les DOIs	https://doi.org/10.1016/j.annonc.2020.08.2099
état	Publié - 1 nov. 2020

Accès au document

10.1016/j.annonc.2020.08.2099

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d4b23b335353452b9aef68ae04a6a2ef,

title = "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†",

keywords = "Clinical Practice Guidelines, adrenal cancer, diagnosis, follow-up, treatment",

author = "{ESMO Guidelines Committee} and M. Fassnacht and G. Assie and E. Baudin and G. Eisenhofer and {de la Fouchardiere}, C. and Haak, {H. R.} and {de Krijger}, R. and F. Porpiglia and M. Terzolo and A. Berruti",

note = "Funding Information: The ESMO Guidelines Committee thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. They also thank the European Cancer Patient Coalition and the following patient organisations for their review: BijnierNET/AdrenalNET. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA, CdlF, GE, FP and Rdk have declared no potential conflicts of interest. Funding Information: MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA , CdlF , GE , FP and Rdk have declared no potential conflicts of interest. ",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/j.annonc.2020.08.2099",

language = "English",

volume = "31",

pages = "1476--1490",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "11",

}

TY - JOUR

T1 - Adrenocortical carcinomas and malignant phaeochromocytomas

T2 - ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

AU - ESMO Guidelines Committee

AU - Fassnacht, M.

AU - Assie, G.

AU - Baudin, E.

AU - Eisenhofer, G.

AU - de la Fouchardiere, C.

AU - Haak, H. R.

AU - de Krijger, R.

AU - Porpiglia, F.

AU - Terzolo, M.

AU - Berruti, A.

N1 - Funding Information: The ESMO Guidelines Committee thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. They also thank the European Cancer Patient Coalition and the following patient organisations for their review: BijnierNET/AdrenalNET. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA, CdlF, GE, FP and Rdk have declared no potential conflicts of interest. Funding Information: MF has declared conducting research sponsored by HRA Pharma, Millendo Therapeutics and Astellas Pharma; EB has declared participation as expert board and has received grants from HRA Pharma; HRH has received research support from HRA Pharma; MT has received honoraria and research grants from HRA Pharma; AB is currently conducting research sponsored by Ipsen and is a member of the speakers' bureau for Ipsen, Novartis and Advanced Accelerator Applications. GA , CdlF , GE , FP and Rdk have declared no potential conflicts of interest.

PY - 2020/11/1

Y1 - 2020/11/1

KW - Clinical Practice Guidelines

KW - adrenal cancer

KW - diagnosis

KW - follow-up

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85091929763&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2020.08.2099

DO - 10.1016/j.annonc.2020.08.2099

M3 - Article

C2 - 32861807

AN - SCOPUS:85091929763

SN - 0923-7534

VL - 31

SP - 1476

EP - 1490

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -